Takeda’s HYQVIA Wins FDA Approval for CIDP Therapy
Takeda has announced that the FDA has approved HYQVIA® for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as...
Dubai’s Arab Health: Leading New Medical Advances
Join us at the Arab Health 2024 conference, set in the vibrant city of Dubai, from January 29 to...
FDA Nods Merck’s Keytruda for Stage III-IVA Cervical Cancer
Merck announced that the FDA has approved KEYTRUDA, their anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for treating patients...
Pfizer Tivdak SLA Accepted by FDA for Priority Cervical Cancer Review
Genmab A/S and Pfizer Inc. announced the FDA’s acceptance of the supplemental Biologics License Application (sBLA) to potentially convert...
ICON Sets Financial Forecast for 2024 Full Year
ICON plc, a global clinical research organization, has projected financial targets for the year ending December 31, 2024. The...
Innovative Merck-Inspirna Deal: New Hope in Cancer Battle
Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc., New York, for the development of...
Revolutionary J-Brain Cargo® Tech in JCR Alexion Deal
JCR Pharmaceuticals Co., Ltd. has entered into a Research Collaboration, Option, and License Agreement with Alexion, AstraZeneca Rare Disease,...
China’s Bold Takeda Choice: LIVTENCITY’s Unique Edge
Takeda has announced the approval of LIVTENCITY® (maribavir) by the National Medical Products Administration (NMPA) of China for treating...
AstraZeneca & Daiichi Breakthrough Trial: New Breast Cancer Therapy Tested
Daiichi Sankyo and AstraZeneca have begun dosing the first patient in two global, randomized Phase 3 trials of their...
Gilead’s $848M Bet on Compugen’s Revolutionary Therapy
Gilead Sciences, Inc. has entered into an agreement with Israeli company Compugen Ltd., a clinical-stage cancer immunotherapy firm, to...